In obese mice, a drug targeting myostatin and ActRII improves bone density in the hind limbs without changing muscle or total weight.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether myostatin/ActRII inhibition consistently increases bone mineral density across preclinical models of obesity and metabolic disease.
A systematic review and meta-analysis of all preclinical studies using myostatin or ActRII inhibitors in obese rodents, comparing bone mineral density outcomes (pQCT or DXA) across interventions, doses, durations, and strains, with quality assessment and heterogeneity analysis.
Whether PG-110 causes an increase in hind limb bone mineral density compared to placebo in obese mice.
A double-blind, randomized, placebo-controlled trial in 60 diet-induced obese C57BL/6N mice, randomized to PG-110 (10 mg/kg weekly) or saline control for two weeks, with hind limb BMD measured by pQCT at baseline and endpoint, blinded to treatment group.
Whether higher exposure to PG-110 correlates with greater increases in hind limb BMD across a population of obese mice.
A prospective cohort of 120 obese mice treated with varying doses of PG-110 (0–20 mg/kg weekly) for two weeks, with weekly BMD measurements and covariate adjustment for baseline weight, sex, and food intake.
Whether mice receiving PG-110 at a single time point have higher BMD than those not receiving it.
A single-time-point comparison of hind limb BMD in 100 obese mice, 50 treated with PG-110 and 50 untreated, matched for age, sex, and baseline weight, with BMD measured by pQCT.
Whether extreme or unexpected increases in BMD occur in individual mice treated with PG-110.
Detailed case reports of 5 mice exhibiting unusually high BMD increases (>20%) after PG-110 treatment, documenting all metabolic and biomechanical variables.